Mutant p53: one name, many proteins.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Genes & Development

• Publication date

  2012-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/gad.190678.112PMID 22713868PMCID PMC3387655
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.

  2012cited by this paper
• Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

  2012influential reference
• Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• The role of mutant p53 in human cancer

  2011cited by this paper
• Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

  2011cited by this paper
• Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

  2011cited by this paper
• Molecular and Cellular Pathobiology Multiple Stress Signals Activate Mutant p 53 In Vivo

  2011influential reference
• Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies

  2011cited by this paper
• Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.

  2011cited by this paper
• Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.

  2011cited by this paper
• Wild-type p53 controls cell motility and invasion by dual regulation of MET expression

  2011cited by this paper
• TopBP1 Mediates Mutant p53 Gain of Function through NF-Y and p63/p73

  2011cited by this paper
• Small-molecule inhibitors of the p53-MDM2 interaction.

  2011cited by this paper
• ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters

  2011cited by this paper
• SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

  2011cited by this paper
• Reactivation of p53: from peptides to small molecules.

  2011influential reference
• Multiple stress signals activate mutant p53 in vivo.

  2011cited by this paper
• A Pin1/mutant p53 axis promotes aggressiveness in breast cancer.

  2011influential reference
• Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.

  2011cited by this paper
• Mutant p53-induced Up-regulation of Mitogen-activated Protein Kinase Kinase 3 Contributes to Gain of Function*

  2010cited by this paper
• In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models.

  2010cited by this paper
• Modulation of the vitamin D3 response by cancer-associated mutant p53.

  2010influential reference
• Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells.

  2010cited by this paper
• p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.

  2010cited by this paper
• The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.

  2010cited by this paper
• Mutant p53 gain-of-function in cancer.

  2010influential reference
• p53 family members in cancer diagnosis and treatment.

  2010cited by this paper
• Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells

  2010cited by this paper
• p53 Research: the past thirty years and the next thirty years.

  2010cited by this paper
• Current strategies to target p53 in cancer.

  2010cited by this paper
• Characterization of Functional Domains Necessary for Mutant p53 Gain of Function*♦

  2010cited by this paper
• Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures

  2010cited by this paper
• Pharmacological reactivation of mutant p53: from protein structure to the cancer patient

  2010cited by this paper
• Mdm2-mediated ubiquitylation: p53 and beyond

  2010cited by this paper
• Molecular and Cellular Pathobiology Cancer Research p 53 Regulates the Ras Circuit to Inhibit the Expression of a Cancer-Related Gene Signature by Various Molecular Pathways

  2010influential reference
• Blinded by the Light: The Growing Complexity of p53.

  2009cited by this paper
• A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis.

  2009cited by this paper
• p53 and metabolism

  2009cited by this paper
• Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences

  2009cited by this paper
• Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.

  2009cited by this paper
• 20 years studying p53 functions in genetically engineered mice

  2009cited by this paper
• The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis

  2009influential reference
• Promyelocytic leukemia protein is required for gain of function by mutant p53.

  2009influential reference
• Mutant p53 drives invasion by promoting integrin recycling.

  2009cited by this paper
• The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53.

  2009cited by this paper
• Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function*

  2009cited by this paper
• When mutants gain new powers: news from the mutant p53 field

  2009influential reference
• The first 30 years of p53: growing ever more complex

  2009influential reference
• Gal‐3 is stimulated by gain‐of‐function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas

  2009cited by this paper
• Wild-type p53 in cancer cells: when a guardian turns into a blackguard.

  2009cited by this paper
• p53 and E2f: partners in life and death

  2009cited by this paper
• Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53

  2008cited by this paper
• Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families

  2008cited by this paper
• Transcriptional control of human p53-regulated genes

  2008cited by this paper
• A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients

  2008cited by this paper
• The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

  2008cited by this paper
• Does control of mutant p53 by Mdm2 complicate cancer therapy?

  2008cited by this paper
• Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway

  2008cited by this paper
• The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs

  2008cited by this paper
• The p53 family and programmed cell death

  2008cited by this paper
• Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy

  2008influential reference
• Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

  2008cited by this paper
• Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?

  2007influential reference
• Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.

  2007cited by this paper
• TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

  2007influential reference
• Protumorigenic overexpression of stathmin/Op18 by gain‐of‐function mutation in p53 in human hepatocarcinogenesis

  2007cited by this paper
• Transcription regulation by mutant p53

  2007cited by this paper
• Interactions of mutant p53 with DNA: guilt by association

  2007cited by this paper
• TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer

  2007cited by this paper
• Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

  2007influential reference
• Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53

  2007cited by this paper
• MDMX: from bench to bedside

  2007cited by this paper
• Mutant p53: an oncogenic transcription factor

  2007cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis.

  2007cited by this paper
• p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM

  2007cited by this paper
• Unleashing the power of p53: lessons from mice and men.

  2006cited by this paper
• Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

  2006cited by this paper
• Mutant p53 gain of function: the NF-Y connection.

  2006cited by this paper
• Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4

  2006cited by this paper
• Transcriptional regulation by p53: one protein, many possibilities

  2006cited by this paper
• A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.

  2006cited by this paper
• The pathological response to DNA damage does not contribute to p53-mediated tumour suppression

  2006cited by this paper
• Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.

  2006influential reference
• The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

  2006influential reference
• p53 mutation heterogeneity in cancer.

  2005cited by this paper
• Tumor-derived p53 mutants induce NF-kappaB2 gene expression.

  2005cited by this paper
• Mutant p53 proteins bind DNA in a DNA structure-selective mode

  2005cited by this paper
• Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters

  2005influential reference
• Temporal dissection of p53 function in vitro and in vivo

  2005cited by this paper
• Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family.

  2005cited by this paper
• Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression

  2005influential reference
• Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice

  2004cited by this paper
• Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

  2004cited by this paper
• Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

  2004influential reference
• Prognostic significance of p53 gene alterations in node-negative breast cancer

  2004cited by this paper
• How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer?

  2004cited by this paper
• Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes

  2004influential reference
• Transcriptional activities of mutant p53: When mutations are more than a loss

  2004cited by this paper

• CLINT1 as a subtype-specific biomarker and a downstream effector of p53-R273H in lung adenocarcinoma migration

  2026cites this paper
• CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas

  2026cites this paper
• Fibrillarin: bridging ribosome biogenesis and apoptosis in cellular stress and disease

  2026cites this paper
• Integrative Computational Analysis of TP53 Exon 5-6 Mutations in Oral Cavity, Prostate, and Breast Cancers in a Senegalese Population.

  2026cites this paper
• Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage.

  2026cites this paper
• The molecular mechanism of temperature-dependent p53C phase separation accelerated by oncogenic mutations: insights from all-atom and coarse-grained molecular dynamics simulations.

  2026cites this paper
• Benzo[a]pyrene promotes gastric cancer progression via activation of the Correa cascade through modulation of the STAT3-TP53-MMP9 molecular axis.

  2026cites this paper
• From Neoantigen Discovery to Immune‐Checkpoint Synergy: Peptide Cancer Vaccines as Precision Tools for Personalised Cancer Therapy

  2026cites this paper
• ELITE: E3 Ligase Inference for Tissue specific Elimination: A LLM Based E3 Ligase Prediction System for Precise Targeted Protein Degradation

  2026cites this paper
• The p53 R181C mutation accumulates through impaired deacetylation by Sirt1 and facilitates tumor development

  2026cites this paper
• Genomic and Evolutionary Determinants of Two-hit Frequencies in Tumor Suppressor Genes

  2026cites this paper
• Structural dynamics of the wild-type p53 DNA-binding domain and hotspot mutants reveal oncogenic conformational shifts.

  2025cites this paper
• Mis-splicing drives loss of function of p53E224D point mutation

  2025cites this paper
• Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations

  2025cites this paper
• The importance of TP53 status in cancer therapy: The example of chronic lymphocytic leukemia

  2025cites this paper
• A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 on chromatin

  2025cites this paper
• Common origin and somatic mutation patterns of composite lymphomas and leukemias

  2025cites this paper
• A systematic evaluation of the therapeutic potential of endogenous-ADAR editors in cancer prevention and treatment

  2025cites this paper
• PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations

  2025cites this paper
• TOR1 AIP1 interacts with p53 to enhance cell cycle dysregulation in prostate cancer progression

  2025cites this paper
• Glutathione reductase underlies the stability of mutant p53 by antagonizing protein glutathionylation

  2025cites this paper
• Phase Separation and Prion‐Like Aggregation of p53 Family Tumor Suppressors: From Protein Evolution to Cancer Treatment

  2025cites this paper
• Unveiling the role of Ndrg1 gene on the oxidative stress induction behind the anticancer potential of styrylquinazoline derivatives

  2025cites this paper
• Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations

  2025cites this paper
• Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer.

  2025cites this paper
• NKX2-5 congenital heart disease mutations show diverse loss and gain of epigenomic, biochemical and chromatin search functions underpinning pathogenicity

  2025cites this paper
• Evaluating the 'ARID' landscape of SWI/SNF complexes with relevance to cancer.

  2025cites this paper
• Novel MSH6 exon 5–6 skipping variant in a Taiwanese family with Lynch syndrome: implications for genetic testing and cancer management

  2025cites this paper
• Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer.

  2025cites this paper
• Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth

  2025cites this paper
• Lipidome atlas of p53 mutant variants in pancreatic cancer

  2025cites this paper
• Key Considerations for a Prostate Cancer mRNA Vaccine.

  2025cites this paper
• Divergent outcomes of neoadjuvant therapy for locally advanced small-cell lung cancer: two cases report and literature review

  2025cites this paper
• Allosteric and Dominant-Negative Effects in a p53 Core Heterotetramer.

  2025cites this paper
• ZNF217 promotes ovarian cancer progression by impacting multiple pivotal steps in the metastatic process

  2025cites this paper
• Impact of ketogenic and fast-mimicking diet in gastrointestinal cancer treatment

  2025cites this paper
• The novel curcumin analogue AKT-100 targets mutant p53 in gynecologic cancer cells

  2025cites this paper
• Epigenetic dysregulation in pancreatic cancer: emerging biomarkers and clinical applications

  2025cites this paper
• Mutant p53 variants differentially impact replication initiation and activate cGAS-STING to affect immune checkpoint inhibition

  2025cites this paper
• Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials.

  2025cites this paper
• Genomic landscape of a long-term surviving patient with metastatic cancer of the larynx: a case report

  2025cites this paper
• Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type

  2025cites this paper
• Chromatin Immunoprecipitation Reveals p53 Binding to G-Quadruplex DNA Sequences in Myeloid Leukemia Cell Lines

  2025cites this paper
• Head and neck tumor organoid biobank for modelling individual responses to radiation therapy according to the TP53/HPV status

  2025cites this paper
• p53 activates circASCC3 to repress R-loops and enhance resistance to chemotherapy

  2025cites this paper
• Exploring the Genetic Orchestra of Cancer: The Interplay Between Oncogenes and Tumor-Suppressor Genes

  2025cites this paper
• Mutant p53 regulates cancer cell invasion in complex three-dimensional environments through mevalonate pathway-dependent Rho/ROCK signaling.

  2025cites this paper
• Coexistence of P53 and KRAS mutations enhances ERK1/2 signaling by inducing EGR1 expression through mutp53 and c-JUN interaction

  2025cites this paper
• Single-cell and spatial transcriptome analyses reveal tumor heterogeneity and immune remodeling involved in pituitary neuroendocrine tumor progression

  2025cites this paper
• Cancer Classification Through p53 Hotspot Mutations: An Ensemble Learning Approach

  2025influential citation
• Role of Amide Proton Transfer Weighted MRI in Predicting MGMTp Methylation Status, p53-Status, Ki-67 Index, IDH-Status, and ATRX Expression in WHO Grade 4 High Grade Glioma

  2025cites this paper
• TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions

  2025cites this paper
• Management of multiple primary prostate malignant tumors: case report of synchronous prostatic adenocarcinoma and lymphoma

  2025cites this paper
• Bypassing the guardian: regulated cell death pathways in p53-mutant cancers

  2025cites this paper
• Evaluation of dual-function molecules containing both Zn-Ionophore and aggregation inhibition moieties for mutant p53 protein reactivation.

  2025cites this paper
• Uterine fibrosarcomatous dermatofibrosarcoma protuberans (FS-DFSP) with COL1A1::PDGFB fusion and concurrent TP53/ERBB2 mutations: Case report and molecular characterization.

  2025cites this paper
• Molecular Characteristics and Treatment Implications of TP53 Gain‐of‐Function Mutations in Non‐Small Cell Lung Cancer

  2025cites this paper
• Recent Expansions in the Potential of Uracil Derivatives as Chemotherapeutic, Antimicrobial, and Antiviral Agents: A Review

  2025cites this paper
• Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review

  2025cites this paper
• Characterization of p53 p.T253I as a pathogenic mutation underlying Li-Fraumeni Syndrome

  2025cites this paper
• Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation

  2025influential citation
• Linking p53 immunostaining to TP53 mutation status in patients with non-small cell lung cancer.

  2025cites this paper
• Variation at the R181 residue of p53 confers loss of p53 DNA binding cooperativity with the retention of mitochondrial-associated apoptosis

  2025cites this paper
• The multifunctional proline-rich domain of p53 tumor suppressor.

  2025cites this paper
• Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage

  2025cites this paper
• TP53 Expression Status Alters Hemoglobinization and Ferroptosis Sensitivity in K-562 Cells

  2025cites this paper
• Gain-of-function mutant p53 regulates long-noncoding RNA LINC00643 to modulate HIF1α in glioblastoma

  2025cites this paper
• New cell lines expanding the diversity of Ewing sarcoma models

  2025cites this paper
• p53: An Immune Ecosystem Manipulator.

  2025cites this paper
• Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis.

  2025cites this paper
• Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53

  2025cites this paper
• Relationship between Ki-67 and P53 immunohistochemical expression and osteosarcoma chemotherapy sensitivity and long-term prognosis.

  2025cites this paper
• MDMX reprograms glycolysis of hepatocellular carcinoma via 14-3-3γ/FOXO1

  2025cites this paper
• Biology of PEST-containing nuclear proteins as potential targets in ovarian cancer (Review)

  2025cites this paper
• Rethinking p16, p53, and HPV in HNCSCC through lessons from glioblastoma subclonal evolution toward patient-centric N-of-1 single-cell RNA sequencing paradigm

  2025cites this paper
• Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 (PDK1) to Promote Proliferation and Migration in Breast Cancer

  2025cites this paper
• p53 Aggregation in cancer: Molecular mechanisms, functional disruptions, and targeted therapies.

  2025cites this paper
• Next-Generation Sequencing Reveals a Diagnostic and Prognostic Role of the TP53 R273C Mutation in Lower-Grade, IDH-Mutant Astrocytomas

  2025cites this paper
• From Genome Guardian to Immune Modulator: The Expanding Roles of Tumor Suppressor p53

  2025cites this paper
• Pancreatic Cancer Organoids: Modeling Disease and Guiding Therapy

  2025cites this paper
• Stromal fibroblastic mutant Trp53 promotes mammary tumor development via enhanced secretion of paracrine factors

  2025cites this paper
• Mutant p53: evolving perspectives

  2025influential citation
• Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo

  2024cites this paper
• Natural Products for Combating Multidrug Resistance in Cancer.

  2024cites this paper
• Fatty acid metabolism-related lncRNA prognostic signature for serous ovarian carcinoma.

  2024cites this paper
• Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

  2024cites this paper
• Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study

  2024cites this paper
• Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions

  2024cites this paper
• Atox1-cyclin D1 loop activity is critical for survival of tumor cells with inactivated TP53

  2024cites this paper
• Artificial intelligence-assisted generative pretrained transformers for applications of ChatGPT in higher education among graduates

  2024cites this paper
• Nanoreceptors promote mutant p53 protein degradation by mimicking selective autophagy receptors

  2024cites this paper
• A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN

  2024cites this paper
• BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer

  2024cites this paper
• Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma

  2024cites this paper
• Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy.

  2024cites this paper
• An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.

  2024cites this paper
• Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response

  2024cites this paper
• Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.

  2024cites this paper
• Ninjurin 2, a Cell Adhesion Molecule and a Target of p53, Modulates Wild-Type p53 in Growth Suppression and Mutant p53 in Growth Promotion

  2024cites this paper
• Doxorubicin catalyses self-assembly of p53 by phase separation

  2024cites this paper